WallStreetZenWallStreetZen

NASDAQ: APVO
Aptevo Therapeutics Inc Stock

Open Broker Account
$3.48+0.15 (+4.5%)
Updated Dec 8, 2022
APVO Price
$3.48
Fair Value Price
$13.09
Market Cap
$17.72M
52 Week Low
$2.67
52 Week High
$8.55
P/E
2.76x
P/B
1.12x
P/S
2.28x
PEG
0.15x
Dividend Yield
N/A
Revenue
$6.78M
Earnings
$6.40M
Gross Margin
100%
Operating Margin
94.36%
Profit Margin
94.4%
Debt to Equity
1.01
Operating Cash Flow
-$19M
Beta
1.12
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

APVO Overview

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how APVO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

APVO ($3.48) is undervalued by 73.41% relative to our estimate of its Fair Value price of $13.09 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
APVO ($3.48) is significantly undervalued by 73.41% relative to our estimate of its Fair Value price of $13.09 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
APVO ($3.48) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more APVO due diligence checks available for Premium users.

Be the first to know about important APVO news, forecast changes, insider trades & much more!

APVO News

Valuation

APVO fair value

Fair Value of APVO stock based on Discounted Cash Flow (DCF)
Price
$3.48
Fair Value
$13.09
Undervalued by
73.41%
APVO ($3.48) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
APVO ($3.48) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
APVO ($3.48) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

APVO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
2.76x
Industry
13.31x
Market
21.39x
APVO is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
APVO is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

APVO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.12x
Industry
4.98x
APVO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

APVO price to earnings growth (PEG)

For valuing profitable companies with growth potential
APVO is good value based... subscribe to Premium to read more.
PEG Value Valuation

APVO's financial health

Profit margin

Revenue
$0.0
Net Income
-$7.6M
Profit Margin
0%
APVO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
APVO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$31.7M
Liabilities
$15.9M
Debt to equity
1.01
APVO's short-term assets ($24.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APVO's short-term assets ($24.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APVO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
APVO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$6.9M
Investing
-$4.0k
Financing
-$500.0k
APVO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

APVO vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
APVO$17.72M+4.50%2.76x1.12x
ENTX$17.86M-1.12%-0.41x1.25x
LEXX$17.38M+0.69%-2.35x2.19x
RNXT$17.29M+1.60%-1.94x2.12x
APM$18.21M+2.00%-1.76x0.80x

Aptevo Therapeutics Stock FAQ

What is Aptevo Therapeutics's quote symbol?

NASDAQ: APVO) Aptevo Therapeutics trades on the NASDAQ under the ticker symbol APVO. Aptevo Therapeutics stock quotes can also be displayed as NASDAQ: APVO.

If you're new to stock investing, here's how to buy Aptevo Therapeutics stock.

What is the 52 week high and low for Aptevo Therapeutics (NASDAQ: APVO)?

(NASDAQ: APVO) Aptevo Therapeutics's 52-week high was $8.55, and its 52-week low was $2.67. It is currently -59.3% from its 52-week high and 30.34% from its 52-week low.

How much is Aptevo Therapeutics stock worth today?

(NASDAQ: APVO) Aptevo Therapeutics currently has 5,091,758 outstanding shares. With Aptevo Therapeutics stock trading at $3.48 per share, the total value of Aptevo Therapeutics stock (market capitalization) is $17.72M.

Aptevo Therapeutics stock was originally listed at a price of $112.00 in Jul 20, 2016. If you had invested in Aptevo Therapeutics stock at $112.00, your return over the last 6 years would have been -96.89%, for an annualized return of -43.93% (not including any dividends or dividend reinvestments).

How much is Aptevo Therapeutics's stock price per share?

(NASDAQ: APVO) Aptevo Therapeutics stock price per share is $3.48 today (as of Dec 8, 2022).

What is Aptevo Therapeutics's Market Cap?

(NASDAQ: APVO) Aptevo Therapeutics's market cap is $17.72M, as of Dec 10, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Aptevo Therapeutics's market cap is calculated by multiplying APVO's current stock price of $3.48 by APVO's total outstanding shares of 5,091,758.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.